References


Jagannath S, Hofmeister CC, Siegel DS, et al. Pomalidomide (POM) with low-dose dexamethasone (LoDex) in patients (pts) with relapsed and refractory multiple myeloma who have received prior therapy with lenalidomide (LEN) and bortezomib (BORT): updated phase 2 results and age subgroup analysis. Paper presented at: American Society of Hematology (ASH) 54th Annual Meeting and Exposition; December 8-11, 2012; Atlanta, GA. (abstr 450)


Pomalyst (pomalidomide) [package insert]. Summit, NJ: Celgene Corporation; May 2014.


Raje N, Vogl DT, Bensinger W, et al. Ricolinostat (ACY-1215), the first selective histone deacetylase 6 inhibitor, is active and well tolerated in combination with lenalidomide or bortezomib in patients with refractory myeloma. Paper presented at: European Hematology Association (EHA); September 5-7, 2014; Barcelona, Spain. (abstr P358)


Richardson PG, Hofmeister C, Raje NS, et al. MM-005: Phase 1 trial of pomalidomide (POM), bortezomib (BORT), and low-dose dexamethasone (LoDEX [PVD]) in lenalidomide (LEN)-refractory and proteasome inhibitor (PI)-exposed myeloma. *J Clin Oncol.* 2014;32:5(suppl; abstr 8589).


